DV
Dividend Vision

BLLN — BillionToOne, Inc.

BillionToOne, Inc. (BLLN)

Total return is -14.3% over the past 0.8 years, 31.1 points behind SPY at 16.8%.

BillionToOne, Inc. is a precision diagnostics company that develops molecular counting technology to detect and measure DNA at the single-molecule level for disease detection and monitoring. The company offers products including UNITY Complete, a non-invasive prenatal screening test; Northstar Select, a tumor liquid biopsy identifying mutations; and Northstar Response, a methylation-based cancer monitoring assay. As an operating company, BillionToOne does not have a stated distribution rate or expense ratio, and appeals to investors interested in exposure to precision medicine and molecular diagnostics technology.

BLLN key facts

Asset type
Stock
Asset class
Equity
Inception date
11/06/2025
Distribution frequency
None
Last close
$93.33
Market cap
$4,403,966,464
Average volume
480900.0
Payout ratio
0.0
P/E ratio
131.4507
Forward P/E
0.0
EPS
$0.71